What I'm saying is NOT mutually exclusive to the issues that Novartis raises.
The point being the data is compromised by the lack of available candidates.
This is because the FDA allowed too many treatments to be trialed simultaneously and MSB was seeking patients who were untreated.
Capito?
So it's hair splitting to say that Novartis weren't looking for a reason to cancel, and for commercial reasons.
Quite obviously they were.
But this will go over your head old boy.
Novartis walked due to "sub par data"., page-138
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |